Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis
暂无分享,去创建一个
[1] Tyler J. VanderWeele,et al. Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.
[2] J. Baddley,et al. Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases , 2017, Arthritis & rheumatology.
[3] P. Merkel,et al. Infections and the risk of incident giant cell arteritis: a population-based, case-control study , 2016, Annals of the rheumatic diseases.
[4] M. Broder,et al. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. , 2016, Seminars in arthritis and rheumatism.
[5] N. Acharya,et al. Assessment of the Accuracy of Using ICD-9 Codes to Identify Uveitis, Herpes Zoster Ophthalmicus, Scleritis, and Episcleritis. , 2016, JAMA ophthalmology.
[6] E. Hedley‐Whyte,et al. Varicella Zoster Virus Infection in Granulomatous Arteritis of the Aorta. , 2016, The Journal of infectious diseases.
[7] D. Gilden,et al. Blinded search for varicella zoster virus in giant cell arteritis (GCA)-positive and GCA-negative temporal arteries , 2016, Journal of the Neurological Sciences.
[8] D. Pisapia,et al. VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. , 2016, Experimental and molecular pathology.
[9] E. Lavi,et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis , 2015, Neurology.
[10] H. Grossniklaus,et al. Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis. , 2015, JAMA neurology.
[11] F. Sloan,et al. Effect of Diabetes Mellitus on Giant Cell Arteritis , 2015, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[12] K. Schmader,et al. Long-term persistence of zoster vaccine efficacy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Hyon K. Choi,et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study , 2014, Annals of the rheumatic diseases.
[14] L. Wilkins. Herpes zoster as a risk factor for stroke and TIA: A retrospective cohort study in the UK , 2014, Neurology.
[15] M. Brown,et al. Herpes zoster as a risk factor for stroke and TIA , 2014, Neurology.
[16] A. Cunningham,et al. Analysis of T Cell Responses during Active Varicella-Zoster Virus Reactivation in Human Ganglia , 2013, Journal of Virology.
[17] C. Weyand,et al. Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.
[18] G. Hunder,et al. Clinical features of polymyalgia rheumatica and giant cell arteritis , 2012, Nature Reviews Rheumatology.
[19] Martin Kulldorff,et al. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. , 2011, Mayo Clinic proceedings.
[20] Y. J. Liao,et al. Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.
[21] S. Bernatsky,et al. The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases , 2011, The Journal of Rheumatology.
[22] S. Gabriel,et al. Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. , 2010, Rheumatology.
[23] Herng‐Ching Lin,et al. Increased Risk of Stroke After a Herpes Zoster Attack: A Population-Based Follow-Up Study , 2009, Stroke.
[24] Javier Martín,et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.
[25] M. Elkind,et al. The varicella zoster virus vasculopathies: Clinical, CSF, imaging, and virologic features , 2009, Neurology.
[26] B. Fernández-Gutiérrez,et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction , 2005, Annals of the rheumatic diseases.
[27] J. Stone,et al. No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[28] M. Esiri,et al. Absence of detection of Varicella-Zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritis , 2003, Journal of the Neurological Sciences.
[29] S. Gabriel,et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.
[30] B. Baslund,et al. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. , 2002, Rheumatology.
[31] R. L. Font,et al. Detection of varicella zoster virus DNA in some patients with giant cell arteritis. , 2001, Investigative ophthalmology & visual science.
[32] C. Nordborg,et al. Search for varicella zoster virus in giant cell arteritis , 1998, Annals of neurology.
[33] M. Russo,et al. Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism? , 1995, Arthritis and rheumatism.
[34] A. B. Hill. The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.
[35] S. Gabriel,et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.
[36] B. Thiers. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults , 2006 .
[37] B. Yawn,et al. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? , 2011, American journal of epidemiology.